The shares of this company engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs) are in the spotlight after the company announced a U.S. pricing agreement that delays Section 232 tariffs on its innovative pharmaceutical products for over two years.
With a market capitalisation of Rs. 4,63,540 cr, the shares of Sun Pharmaceutical Industries Ltd were trading at Rs. 1932 per share, up from its previous close of Rs. 1,930.45 per share.
Sun Pharma – U.S. Pricing Agreement
Sun Pharmaceutical Industries Ltd has taken part in a White House signing ceremony where agreements between pharmaceutical companies and the U.S. government were announced to increase access to low-cost medications. According to the deal, Sun Pharma would offer Most Favored Nation (MFN) pricing to U.S. state Medicaid programs and also commit to MFN pricing on innovative medications.
One of the main advantages for Sun Pharma is that the agreement grants the company a deferment of Section 232 tariffs on innovative pharmaceuticals for more than two years. Although the exact commercial details are not disclosed, the tariff deferment should help Sun Pharma improve its understanding of costs and ensure the viability of its innovative medicines business in the U.S.
The United States is an important market for Sun Pharma, which earns about 27% of its revenues from the U.S. and it is their largest market for innovative medicines. Sun Pharma has established itself as a dominant force in dermatology, immunology, cutaneous oncology, and ophthalmology; apart from that, it also has significant generics and consumer healthcare business. Sun Pharma occupies the number two position in the U.S. dermatology market in terms of prescriptions.
The announcement also highlights Sun Pharma’s increasing commitment to the U.S. market. Earlier this year, the company entered into a definitive agreement to acquire Organon & Co. at an enterprise value of $11.75 billion, reinforcing its strategy of expanding its innovative medicines portfolio and strengthening its presence in the U.S.
HSBC on Sun Pharma
HSBC maintained a Buy rating on Sun Pharma with a target price of Rs. 2,120, which is a 10% upside from the current levels, noting that the MFN agreement significantly reduces the tariff overhang by delaying Section 232 tariffs for two years. It expects the deal to have a limited ~2% impact on its FY29 EPS estimate, while awaiting further clarity on the pricing terms.
Morgan Stanley on Sun Pharma
Morgan Stanley believes the agreement reduces uncertainty around U.S. tariffs, as Section 232 tariffs on Sun Pharma’s innovative medicines are delayed for more than two years. While MFN-related pricing adjustments could affect earnings, the brokerage expects the impact to remain limited as Medicaid accounts for only a small portion of Sun Pharma’s U.S. innovative-medicine sales.
Bernstein on Sun Pharma
Bernstein maintained an Outperform rating with a target price of Rs. 2,235, which is a 16% upside from the current levels, calling the agreement strategically important as it protects and supports Sun Pharma’s $1.2–1.3 billion innovative-medicines franchise.
The timing is particularly relevant for Ilumya ahead of its October 29 PDUFA date, while the tariff protection could also safeguard margins across the generics portfolio and future Organon-led launches.
Overall, Sun Pharma’s U.S. tariff relief could unlock further upside for the stock by reducing regulatory and cost uncertainty and protecting margins in its innovative-medicines business. With brokerages maintaining positive views and target prices implying 10–16% upside, the agreement strengthens the near-term outlook, although MFN-related pricing pressure remains a key factor to monitor.